Evidence map›Paper›PMID 40553419›Full record

Observational studyTargeted oncology2025

Relationship of Prior Anticancer Treatments with Palbociclib Clinical Outcomes in Patients with HR

Gabrielle B Rocque, Joanne L Blum, Yan Ji, Timothy Pluard, John Migas, Shailendra Lakhanpal, Erin Jepsen, Yao Wang, Monica Z Montelongo, Zhe Zhang and 2 more

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Targeted oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03280303 (POLARIS), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03280303 completednot on this map

Polaris: palbociclib in hormone receptor positive advanced breast cancer: a prospective multicenter non-interventional study

TypeobservationalSponsorPfizerRan2017 to 2022Enrolled1,285ConditionsAdvanced Breast Cancer, Metastatic Breast CancerArmsnon-interventional
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gabrielle B RocqueDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL, 35294, USA. grocque@uabmc.edu.ORCID http://orcid.org/0000-0003-4188-9785
Joanne L BlumTexas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.
Yan JiHematology/Oncology, Health Partners Institute, Saint Paul, MN, USA.
Timothy PluardSt. Luke's Hospital Koontz Center for Advanced Breast Cancer, Kansas City, MO, USA.
John MigasMid-Illinois Hematology and Oncology Associates, Normal, IL, USA.
Shailendra LakhanpalAlabama Oncology, Birmingham, AL, USA.
Erin JepsenMedical Oncology, Hematology, Novant Health Cancer Institute, Winston-Salem, NC, USA.
Yao WangOncology Pfizer Biopharma, Pfizer Inc, New York, NY, USA.
Monica Z MontelongoICON plc, Blue Bell, PA, USA.
Zhe ZhangOncology Clinical Statistics, Pfizer Inc, La Jolla, CA, USA.
Eric GauthierPfizer Inc, South San Francisco, CA, USA.
Debu TripathyDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the real-world POLARIS study, patients with hormone receptor-positive (HR

objectiveThe aim of this study is to assess the relationship of prior anticancer treatments with clinical outcomes. PATIENTS AND

methodsKaplan-Meier estimates of rwPFS and overall survival (OS) are described by prior anticancer treatments in patients with HR

resultsA total of 1250 patients received ≥ 1 palbociclib dose (1LOT: 901 [72.1%]; ≥ 2LOT: 349 [27.9%]). In the 1LOT group, 563 (62.5%) had received prior (neo)adjuvant treatments: 24.3% ET alone, 26.6% chemotherapy alone, 45.5% ET + chemotherapy, and 3.6% other treatments; both median rwPFS and OS were numerically longer in patients who had received ET alone (30.4 months and not reached, respectively) and had had no prior treatment (23.7 and 53.3 months, respectively) than in patients with prior chemotherapy alone (15.9 and 38.4 months, respectively). In the ≥ 2LOT group, patients with prior ET alone (21.5%; 19.8 months) or chemotherapy alone (16.6%; 15.5 months) in the (neo)adjuvant and/or metastatic setting had numerically longer median rwPFS than those with prior ET + chemotherapy (41.3%; 11.6 months); OS was comparable regardless of prior treatment.

conclusionsPatients with HR

trial registrationClinicalTrials.gov, NCT03280303.

Indexed as

Antineoplastic AgentsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesPiperazinesPyridinesAdultAgedFemaleHumansMiddle AgedReceptors, EstrogenReceptors, ProgesteroneTreatment OutcomeAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespalbociclibPiperazinesPyridinesReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID40553419
PMCPMC12307473

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.